Health Care

Johnson & Johnson’s latest 2026 report reveals early promise for pasritamig + docetaxel in advanced prostate cancer and launches new, infection‑reduced aspiration catheters, boosting both drug and device portfolios.

Fresenius Medical Care AG tops Q4 2025 forecasts, boosting EBITDA & revenue while navigating U.S. Medicare caps and EU RDI pressures – a promising recovery with tele‑dialysis and AI opportunities.

Dupixent’s new EU pediatric CSU indication, backed by LIBERTY‑CUPID trials, promises first‑of‑its‑kind targeted relief for 2‑11‑year‑olds, boosting Regeneron’s market reach and patient care.

Labcorp’s steady growth, strong margins, and AI‑driven expansion into tele‑lab, at‑home testing and genomic services position the diagnostics leader to capture rising reimbursement opportunities while boosting patient access and cost efficiency.

Discover how Eisai’s Kompass platform and Leqembi therapy blend digital health, patient care, and oncology‑neuro synergy to reshape pharma.

Amgen’s steady share price, backed by solid earnings and promising biotech pipeline, shows potential upside as Phase 3 data for AMG 301, AMG 701, and AMG 510 emerge.

Royalty Pharma’s short‑interest fell 50% in February, easing bearish pressure while the company gears up for a TD Cowen fireside chat to discuss strategy, reimbursement, and growth.

Discover how Steris Public Limited Company’s infection‑control solutions power global hospital growth, driving innovation and investor confidence.

Thermo Fisher Scientific boosts its dividend to $0.47 per share, underscoring steady earnings and continued investment in lab‑equipment that enhance diagnostics and patient care.

Investors: Explore Centene’s flat stock, low valuations, and regulatory risks while spotting telehealth, AI, and value‑based care upside.